482 related articles for article (PubMed ID: 29455659)
1. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.
Ghosh S; Marrocco I; Yarden Y
Adv Cancer Res; 2020; 147():1-57. PubMed ID: 32593398
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
Jiang W; Ji M
Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
[TBL] [Abstract][Full Text] [Related]
7. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision.
Huang XL; Khan MI; Wang J; Ali R; Ali SW; Zahra QU; Kazmi A; Lolai A; Huang YL; Hussain A; Bilal M; Li F; Qiu B
Int J Biol Macromol; 2021 Jun; 180():739-752. PubMed ID: 33737188
[TBL] [Abstract][Full Text] [Related]
8. Acquired Resistance Is Oncogene and Drug Agnostic.
Doebele RC
Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
[TBL] [Abstract][Full Text] [Related]
9. Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer.
Sáez JM
Anticancer Agents Med Chem; 2013 Mar; 13(3):483-95. PubMed ID: 22583421
[TBL] [Abstract][Full Text] [Related]
10. Breaking Oncogene Addiction: Getting RTK/RAS-Mutated Cancers off the SOS.
Sheffels E; Kortum RL
J Med Chem; 2021 May; 64(10):6566-6568. PubMed ID: 33961431
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinases as targets in cancer therapy - successes and failures.
Traxler P
Expert Opin Ther Targets; 2003 Apr; 7(2):215-34. PubMed ID: 12667099
[TBL] [Abstract][Full Text] [Related]
12. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Sakle NS; More SA; Dhawale SA; Mokale SN
Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
[TBL] [Abstract][Full Text] [Related]
13. Emerging Targeted Therapy for Tumors with
Kheder ES; Hong DS
Clin Cancer Res; 2018 Dec; 24(23):5807-5814. PubMed ID: 29986850
[TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to drugs targeting receptor tyrosine kinases.
Rosenzweig SA
Biochem Pharmacol; 2012 Apr; 83(8):1041-8. PubMed ID: 22227013
[TBL] [Abstract][Full Text] [Related]
15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
16. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
17. A historical overview of protein kinases and their targeted small molecule inhibitors.
Roskoski R
Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation.
Narayanan R; Yepuru M; Coss CC; Wu Z; Bauler MN; Barrett CM; Mohler ML; Wang Y; Kim J; Snyder LM; He Y; Levy N; Miller DD; Dalton JT
PLoS One; 2013; 8(12):e83380. PubMed ID: 24386191
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of receptor tyrosine kinase activation in cancer.
Du Z; Lovly CM
Mol Cancer; 2018 Feb; 17(1):58. PubMed ID: 29455648
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T
Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
